Taking decisions on expenditure for high-cost drugs at the regional level: A model for evaluating the overall impact of Trastuzumab in the Veneto Region of Italy

Journal of Evaluation in Clinical Practice

Volumn 17, Issue 2, 2011, Pages 298-303

  Buja, Alessandra ^a   Perissinotto, Egle ^a   Compostella, Antonio ^b   Tramarin, Andrea ^b   Rebba, Vincenzo ^a   Pastorelli, Davide ^c   Grigoletto, Francesco ^a   Gallo, Costantino ^b   Rausa, Giuseppe ^a   Gregori, Dario ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Agenzia Regionale Socio Sanitaria del Veneto   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Cost of drug treatment; Cost consequence analysis; Epidemiology model; Resource planning

Indexed keywords

TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; COST BENEFIT ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE POLICY; ITALY; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROBABILITY;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DECISION MAKING; DRUG COSTS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; ITALY; MARKOV CHAINS; MIDDLE AGED; MODELS, THEORETICAL; RESOURCE ALLOCATION; YOUNG ADULT;

EID: 79952634673     PISSN: 13561294     EISSN: 13652753     Source Type: Journal    
DOI: 10.1111/j.1365-2753.2010.01440.x     Document Type: Article

References (20)

1. Davies, L., Coyle, D. & Drummond, M. (1994) Current status of economic appraisal of health technology in the European Community: report of the network. The EC Network on the Methodology of Economic Appraisal of Health Technology. Social Science & Medicine, 38, 1601-1607. [Medline].
2. Russell, L. B., Gold, M. R., Siegel, J. E., Daniels, N. & Weinstein, M. C. (1996) The role of cost-effectiveness analysis in health and medicine. JAMA, 276, 1172-1177. (Pubitemid 26329746)
3. Drummond, M., Brown, R., Fendrick, A. M., Fullerton, P., Neumann, P., Taylor, R. & Barbieri, M. (2003) Use of pharmacoeconomics information. Report of the ISPOR task force on use of pharmacoeconomic/health economic information in health-care decision making. Value in Health, 6, 407-416. (Pubitemid 36929727)
4. Mauskopf, J. A., Paul, J. E., Grant, D. M. & Stergachis, A. (1998) The role of cost-consequence analysis in healthcare decision-making. Pharmacoeconomics, 13, 277-288. [Medline].
5. SISTAR (Statistical System Veneto Region) (2006) Popolazione residente per sesso e per classe d'età. Available at: http://statistica.regione. veneto.it/dati-settoriali-popolazione.jsp (last accessed 31 December 2009).
6. Veneto Register of Tumor (2007) Fatti e cifre dei tumori in Veneto. Available at: http://www.registrotumoriveneto.it/ (last accessed 31 December 2009).
7. Slamon, D. J., Godolphin, W., Jones, L. A., et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-712. (Pubitemid 19147683)
8. Neyt, M., Huybrechts, M., Hulstaert, F., Vrijens, F. & Ramaekers, D. (2008) Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium. Health Policy, 87, 146-159. [Medline].
9. Romond, E. H., Perez, E. A., Bryant, J., et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine, 353, 1673-1684. [Abstract/Full Text].
10. Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., et al.; Herceptin Adjuvant (HERA) Trial Study Team (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of Medicine, 353, 1659-1672. [Abstract/Full Text].
11. UVEF Verona (Unit for valuation of drug efficacy in Veneto) (2007) Schede HTA Farmaci. Trastuzumab. Available at: http://www.uvef.it/web/index.php?pag= schede-informative-suifarmaci&lettera=T&num=1 (last accessed 31 December 2009).
12. Veneto Region Tariff (2007) DGR 11.12., n. 4051 - Istituzione del 'Fondo regionale per i farmaci oncologici ad alto costo erogati in regime ambulatoriale' e del 'Sistema informativo regionale sui farmaci ad alto costo erogati in regime ambulatoriale'. (BUR n. 7 del 22.1.08).
13. Regione Veneto (2005) Nomenclature of Tariff for Veneto Region. Available at: http://www.simel.it/download/100341-documento.pdf (last accessed 31 December 2009).
14. Marchetti, M., Caruggi, M. & Colombo, G. (2004) Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service. Clinical Therapeutics, 26, 1546-1561 [Medline].
15. Galper, S., Blood, E., Gelman, R., et al. (2005) Prognosis after local recurrence after conservative surgery and radiation for early-stage breast cancer. International Journal of Radiation Oncology, Biology, Physics, 61, 348-357. (Pubitemid 40164426)
16. Sonnenberg, F. A. & Beck, J. R. (1993) Markov models in medical decision making: a practical guide. Medical Decision Making, 13, 322-338. [Abstract].
17. Favaretti, C. & De Pieri, P. (2008) La valutazione delle tecnologie sanitarie in Italia: seconda fase. Clinical Governance, 1, 1-4.
18. Liberato, N. L., Marchetti, M. & Barosi, G. (2007) Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. Clinical Oncology, 25, 625-633. (Pubitemid 350002916)
19. National Institute for Health and Clinical Excellence (NICE) (2006) Trastuzumab for the Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer. London: National Institute for Health and Clinical Excellence (NICE).
20. Barrett, A., Roques, T., Small, M. & Smith, R. D. (2006) How much will Herceptin really cost? BMJ, 333, 1118-1120. [Full Text].